Recent Finacing
Recent Raise
Actuate Therapeutics is a clinical-stage biopharmaceutical company developing 9‑ING‑41, a GSK‑3β inhibitor, conducting the 1801 Phase 1/2 histology-agnostic trial of single-agent and chemotherapy combination regimens.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Actuate Therapeutics.
